Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

In vitro studies have demonstrated that angiotensin (Ang) II directly stimulates vascular smooth muscle cell (VSMC) growth. However, it is still unclear if Ang II exerts a direct effect on vascular hypertrophy in vivo independent of its effect on blood pressure. In vivo gene transfer provides the opportunity to assess the effects of increased activity of the vascular angiotensin system in the intact animal while avoiding an increase in circulating angiotensin or in blood pressure. Accordingly, we transfected the human angiotensin converting enzyme (ACE) vector into intact rat carotid arteries by the hemagglutinating virus of Japan-liposome method. 3 d after transfection, we detected increased ACE activity in the transfected artery. Immunohistochemistry localized immunoreactive ACE in the medial VSMC as well as in the intimal endothelial cells. The increase in vascular ACE activity was associated with a parallel increase in DNA synthesis as assessed by BrdU (bromo-deoxyuridine) index and vascular DNA content. This increase in DNA synthesis was abolished by the in vivo administration of an Ang II receptor-specific antagonist (DuP 753). Morphometry at 2 wk after transfection revealed an increase in the wall to lumen ratio of the ACE-transfected blood vessel as compared with control vector transfected vessels. This was accompanied by increases in protein and DNA contents without an increase in cell number. Local transfection of ACE vector did not result in systemic effects such as increased blood pressure, heart rate, or serum ACE activity. These morphological changes were abolished by the administration of the Ang II receptor antagonist. In this study, we used in vivo gene transfer to increase local expression of vascular angiotensin converting enzyme and provided proof that increased autocrine/paracrine angiotensin can directly cause vascular hypertrophy independent of systemic factors and hemodynamic effects. This approach has important potentials for defining the role of autocrine/paracrine substances in vascular biology and hypertension.

[1]  M. Safar,et al.  Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. , 1988, Circulation research.

[2]  V. Dzau,et al.  Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[3]  T. Ogihara,et al.  Novel and effective gene transfer technique for study of vascular renin angiotensin system. , 1993, The Journal of clinical investigation.

[4]  M. Daemen,et al.  Alpha 1-adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery. , 1992, Circulation research.

[5]  G. Gibbons,et al.  Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. , 1992, The Journal of clinical investigation.

[6]  G. Owens,et al.  Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells , 1988, The Journal of cell biology.

[7]  M. Mulvany,et al.  Angiotensin II Causes Vascular Hypertrophy in Part by a Non‐pressor Mechanism , 1991, Hypertension.

[8]  M. Mulvany Are Vascular Abnormalities a Primary Cause or Secondary Consequence of Hypertension? , 1991, Hypertension.

[9]  D. Ganten,et al.  Angiotensin and cell growth: a link to cardiovascular hypertrophy? , 1991, Journal of hypertension.

[10]  G. Gibbons,et al.  Molecular Mechanisms of Vascular Renin‐Angiotensin System in Myointimal Hyperplasia , 1991, Hypertension.

[11]  G. Owens Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat. , 1985, Circulation research.

[12]  V. Dzau The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. , 1993, Current opinion in nephrology and hypertension.

[13]  P Corvol,et al.  Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Miyazaki,et al.  Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. , 1986, Hypertension.

[15]  T. Resink,et al.  Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. , 1990, Journal of cardiovascular pharmacology.

[16]  M. Mulvany,et al.  Cellular Hypertrophy in Mesenteric Resistance Vessels from Renal Hypertensive Rats , 1988, Hypertension.

[17]  D W Cushman,et al.  Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. , 1971, Biochemical pharmacology.

[18]  G. Owens,et al.  Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. , 1987, Hypertension.

[19]  D. Campbell,et al.  Circulating and tissue angiotensin systems. , 1987, The Journal of clinical investigation.

[20]  K. Iwai,et al.  Introduction and expression of the human insulin gene in adult rat liver. , 1989, The Journal of biological chemistry.

[21]  R. Sivertsson The hemodynamic importance of structural vascular changes in essential hypertension. , 1970, Acta physiologica Scandinavica. Supplementum.

[22]  A. Lever Angiotensin II, angiotensin-converting enzyme inhibitors, and blood vessel structure. , 1992, The American journal of medicine.

[23]  J. Krieger,et al.  Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. , 1994, The Journal of clinical investigation.

[24]  R. Prewitt,et al.  Captopril Reduces Aortic and Microvascular Growth in Hypertensive and Normotensive Rats , 1990, Hypertension.

[25]  M. Peach,et al.  Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells , 1988, Circulation research.

[26]  G. Gibbons,et al.  Endothelium and Growth Factors in Vascular Remodeling of Hypertension , 1991, Hypertension.

[27]  C. Triggle,et al.  Prevention of Hypertension and Vascular Changes by Captopril Treatment , 1991, Hypertension.

[28]  R. Kauffman,et al.  Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. , 1991, Life sciences.

[29]  B. Berk,et al.  Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. , 1989, Hypertension.

[30]  H. Schunkert,et al.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. , 1990, The Journal of clinical investigation.

[31]  T. Ogihara,et al.  Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. , 1992, Hypertension.

[32]  T. Saruta,et al.  Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells , 1991, Journal of hypertension.

[33]  D. Ganten,et al.  The Molecular Basis of Cardiovascular Hypertrophy: The Role of the Renin‐Angiotensin System , 1992, Journal of cardiovascular pharmacology.

[34]  M. Miyazaki,et al.  Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. , 1992, Hypertension.

[35]  L. Dwoskin,et al.  Acute and chronic effects of losartan (DuP 753) on blood pressure and vascular reactivity in normotensive rats. , 1993, Clinical and experimental hypertension.

[36]  H. Baumgartner,et al.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.